


ohhhmics | Associate Professor at ETSmtl & CRCHUM | 🐶☕️ 🐥🐒 pellanchenglab.github.io/#jo…


This is a "detective story" paper that shows how setting up the right negative controls can lead to real discoveries. Basically, the authors wanted to reproduce a published result showing that a specific CRISPR tool, called Csm, could chop up RNA molecules and lower their levels in a cell. They measured this with RT-qPCR, a common experiment that quantifies how much of a given RNA is present before and after the CRISPR knockdown. When they went to reproduce this result, they found that Csm did reduce RNA levels. But a negative control, a mutated version of Csm that shouldn't be able to cut anything, also knocked down RNA by roughly the same amount. Weird! So the authors started varying the experimental parameters to solve this dilemma. First, they tried different RNA extraction methods and tested several more CRISPR tools. They confirmed, too, that the mutant Csm couldn't cut RNA. The RT-qPCR results persisted anyway. Second, they built an mCherry reporter to measure protein levels directly. Normal Csm reduced protein levels, which makes sense since it's cutting the RNA. Mutant Csm did not change protein levels at all. This was another good sign that the mutant Csm was producing some kind of artifact. To figure out why, we need to talk about RT-qPCR. This is a method that, first, converts RNA into DNA using reverse transcriptase, an enzyme that builds a matching DNA copy. qPCR then counts how many DNA copies got made from a short stretch of that RNA, called an amplicon. More copies of DNA = more RNA was present at the start. Normally, scientists place this amplicon so that it overlaps with the guide RNA's binding site, since that's the region expected to get cut. But with mutant Csm, an amplicon located at the guide RNA site showed false knockdowns. When the amplicon was moved to *before* the binding site, the artifact disappeared and RNA levels appeared unchanged. Why was this happening? The reason, oddly, was that the guide RNAs (without any protein!) were blocking reverse transcription, making it look like mutant Csm was reducing RNA levels. The researchers tested this by spiking synthetic guide RNA, made with no CRISPR protein at all, directly into the reverse transcription reaction. This reproduced the false knockdown. If a guide RNA can bind a target without a CRISPR protein at all, then we should also see similar gene silencing in cells. Right? Well, no; it turns out guide RNAs break down quickly in cells unless a CRISPR protein binds and stabilizes them. The proteins protect the guide RNA. So TL;DR: guide RNAs can bind a target and block reverse transcription in test tubes. This causes weird experimental artifacts and likely means dozens of CRISPR papers that used RT-qPCR are wrong, in either a minor or possibly major way.

Beautiful paper by beautiful people. Congrats @ntekasi !
Our work @lena_tkys, @dwmckellar, @IwijnDeVlaminck now out in @NatureMicrobiology! 🎉 Spatial transcriptomics maps host–gut microbiome biogeography at high resolution rdcu.be/e7i7o


🔬 We have an opening for a postdoctoral fellow in my lab at Weill Cornell in NYC. This position is ideal for a rigorous, hands-on experimental biologist who loves designing and executing complex wet lab experiments. The focus is on mechanistic cancer biology in cell lines and patient-derived models, with genomics and AI tools integrating with the core bench work. Details below. 👉 Please share with strong experimental candidates in your network. #Postdoc #PostdocJobs #AcademicJobs #CancerResearch #MolecularBiology #WetLab #ScienceCareers #AcademicTwitter
Please spread the word. We are looking for outstanding postdoctoral researchers interested in studying cancer evolution! 🌟 See our recent work nature.com/articles/s41586-0… Details here: bit.ly/436GzMc

when i write "we" in a paper, i'm referring to myself and the voices.

We believe that these sorts of innovation will greatly serve the at large genomics community. More innovation = more options for scientists = more discoveries. Super exciting. Let's gooooooo!

Massive team effort. A huge thank you to the @UltimaGenomics team, our clinical collaborators and sequencing team @nygenome. Look at the author list, it's huge! Takes a village. Super proud of trainees Aaron, Sam and Sri

Patient vignettes in lung cancer patients also show concordance with scans. A huge thank you to our collaborators Drs Altorki and Saxena

We looked at patients with urothelial cancer, and found strong correlation between tumor-informed and tumor naive measurements. Great collaboration with @FaltasLab

But what if you don't have the tumor? DOESN'T MATTER. ppmSeq is so error robust that you don't need tumor sequencing to detect ctDNA. Hello, new era of tumor-naive patient monitoring.

Application 1: tumor-informed ctDNA detection. ppmSeq is perfectly suited for this. We sequence the tumor, and mine for mutations in the blood with ppmSeq. This enabled part per TEN MILLION ctDNA detection. PAR PER 10M. Insanity.

ppmSeq is a broad DNA sequencing method. The applications are endless. We looked at 2:

Error rate analysis in sperm gDNA (🙏 @giladevrony) and cell-free DNA shows comparable error rates to duplex technologies.

Initial benchmarking shows massive scalability of ppmSeq, ~40-60% of our reads encode dsDNA molecules. The more you sequence, the more get dsDNA CRAZY STAT: ppmSeq is a PCR-FREE method that works with ONE NANOGRAM of input. ONE!!!

You can ID Watson and Crick strands using a mismatched adapter, and single-stranded artifacts cause a conflicting sequencing signal > this is naturally encoded as a low-quality base. You then just filter out the error!